Teleflex Incorporated (NYSE:TFX) to Post FY2025 Earnings of $15.11 Per Share, Zacks Research Forecasts

Teleflex Incorporated (NYSE:TFX - Free Report) - Investment analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Teleflex in a research report issued to clients and investors on Monday, April 1st. Zacks Research analyst R. Department now anticipates that the medical technology company will post earnings per share of $15.11 for the year, down from their previous estimate of $15.24. The consensus estimate for Teleflex's current full-year earnings is $13.73 per share. Zacks Research also issued estimates for Teleflex's Q4 2025 earnings at $3.88 EPS and FY2026 earnings at $16.22 EPS.

Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, February 22nd. The medical technology company reported $3.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.26 by $0.12. The business had revenue of $773.90 million during the quarter, compared to analysts' expectations of $769.01 million. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. Teleflex's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.52 EPS.

TFX has been the topic of several other research reports. Truist Financial dropped their price objective on Teleflex from $270.00 to $265.00 and set a "hold" rating on the stock in a research note on Friday, February 23rd. Royal Bank of Canada lowered their price objective on shares of Teleflex from $272.00 to $265.00 and set an "outperform" rating on the stock in a research note on Friday, February 23rd. StockNews.com lowered shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, February 23rd. Raymond James upped their price target on shares of Teleflex from $227.00 to $271.00 and gave the company an "outperform" rating in a research note on Wednesday, December 20th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $285.00 price target on shares of Teleflex in a research note on Friday, February 23rd. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $265.56.

Teleflex Price Performance

NYSE TFX traded down $2.65 during trading hours on Wednesday, reaching $214.74. 327,454 shares of the company's stock were exchanged, compared to its average volume of 262,788. The stock has a market cap of $10.11 billion, a PE ratio of 28.86, a price-to-earnings-growth ratio of 2.13 and a beta of 1.11. Teleflex has a one year low of $177.63 and a one year high of $276.43. The firm has a fifty day moving average of $234.14 and a 200-day moving average of $224.46. The company has a current ratio of 2.32, a quick ratio of 1.29 and a debt-to-equity ratio of 0.39.

Hedge Funds Weigh In On Teleflex

Several large investors have recently modified their holdings of the business. Kentucky Retirement Systems grew its stake in Teleflex by 1.1% during the fourth quarter. Kentucky Retirement Systems now owns 3,760 shares of the medical technology company's stock valued at $938,000 after acquiring an additional 42 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in Teleflex by 0.9% during the 1st quarter. Commonwealth Equity Services LLC now owns 4,688 shares of the medical technology company's stock valued at $1,187,000 after buying an additional 42 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in Teleflex by 33.3% during the 4th quarter. Venturi Wealth Management LLC now owns 184 shares of the medical technology company's stock valued at $46,000 after buying an additional 46 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Teleflex by 3.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 1,411 shares of the medical technology company's stock valued at $284,000 after buying an additional 48 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in Teleflex by 39.1% during the 1st quarter. First Horizon Advisors Inc. now owns 178 shares of the medical technology company's stock valued at $45,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Insider Buying and Selling

In related news, VP Cameron P. Hicks sold 7,401 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the sale, the vice president now owns 10,050 shares in the company, valued at $2,261,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.41% of the stock is currently owned by corporate insiders.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend was Thursday, February 29th. Teleflex's payout ratio is currently 18.06%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.